JAK2 and cancer: The non-responders to the drug seem to have genes including ICAM1, TUBB2A, GLDC, PLAU, AURKA, NEAT1, MXRA5, GSN, and MUC16 that promote cancer growth and cell proliferation through dysregulation of JAK2, STAT3, MAPK, AKT, and mTOR as well as DNA damage via BRCA1/2 and TP53.